INTRODUCTION

Diabetes is one of the most prevalent endocrine disorders during pregnancy. It is classified as gestational diabetes (diabetes which was first diagnosed during pregnancy) or pre-gestational diabetes. GDM occurs in 2-6% of pregnant women in North America that is estimated 10 times more than pre-gestational diabetes.1,2

In Iran, the prevalence of gestational diabetes has been reported between 4.7-7.4% in different regions that according to the new ADA criteria, the prevalence of gestational diabetes will be much higher than the above numbers.3-5 About 10-15% of pregnant women have thyroid dysfunction during the first half of pregnancy, which may be hypothyroidism or hyperthyroidism.6 However, the prevalence of thyroid dysfunction in pregnant women with type I diabetes is about three times more than general population and subclinical hypothyroidism is more prevalent.7

In some studies 40% of pregnant women with type I diabetes may also have thyroid dysfunction simultaneously.8 Some studies have reported high incidence of hypothyroxinemia and high Anti TPO

ABSTRACT

Objective: The aim of this study was to investigate thyroid function tests in Gestational Diabetes Mellitus (GDM) and pre-gestational DM and control group.

Methodology: There were 61 pregnant diabetic women in study group and 35 pregnant women in control group. Serum T4, T3, T3RU, FTI, TSH and Anti TPO Ab were assessed in each person.

Results: About 36% of patients had GDM and 64% pre-gestational DM. Thyroid dysfunction was detected in 18% of study group compared with 8.6% of control group (P = 0.2). There was Thyroid dysfunction in 4.5% of GDM and 25.6% of pregestational DM (P = 0.045). There was no statistically significant difference between thyroid dysfunction in GDM group and control group (P=0.99).27% of GDM and 36% of pregestational DM and 23% of control group had positive titer of Anti TPO Ab without statistically significant differences among the three groups.

Conclusion: Thyroid dysfunction is prevalent in women with pre-gestational DM so, thyroid function should be evaluated in these patients during pregnancy. Rate of thyroid dysfunction in GDM patients is similar to normal pregnant control women. High prevalence of positive titer of TPO Ab was seen in diabetic and non-diabetic pregnant women.

KEY WORDS: Thyroid dysfunction, GDM, Pregestational DM, Anti TPO Ab, Anti TgAb.

doi: http://dx.doi.org/10.12669/pjms.292.2862
titer in GDM. Prevalence of high titer of Anti TPO Ab in healthy pregnant women and type 1 diabetes also have significant difference. Delayed diagnosis of hypothyroidism in pregnancy leads to congenital malformations and respiratory distress in newborns of these mothers.

Furthermore mother’s diabetes during pregnancy can influence the secretion of T3 or conversion of T4 to active T3 in the fetus and premature newborns. When anti-thyroid antibodies are positive, there is risk of premature rupture of amniotic sac and preterm labor. Some studies have showed that even without the overt thyroid dysfunction, autoimmune thyroid disease increases abortion rates up to 3 to 5 times.

The purpose of this study was to evaluate thyroid function tests and thyroid autoantibody level in pregnant patients with diabetes (GDM and pre-gestational diabetes) and comparison with a non-diabetic control group in Ahvaz (Western South of Iran).

**METHODOLOGY**

This is a cross sectional prospective study. The study population was pregnant women with diabetes (pre-gestational diabetes and gestational diabetes) who were referred to Ahvaz Golestan Hospital Endocrinology Clinic from 2004 to 2006. Diabetic patients were aged 19 to 47 years. Thirty five non-diabetic pregnant women were also considered as control group. Sequential sampling was conducted. Written consent was obtained from all patients and the study was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Science.

In this study T3, T4, TSH, T3RU and Anti TPO Ab were measured in all GDM and pre-gestational diabetic pregnant women and control group. T3, T4, T3rU, FTI hormones was measured by RIA method, TSH by IRMA, TPO Ab by ELISA, Counter. Kits used in this laboratory was Immunotech product of A Beckman coulter company made in America. Pre-gestational diabetes had been distinguished before pregnancy. GDM in pregnant women had been considered if two of the four criteria were detected following 100 g glucose tolerance test:(FBS ≥ 95, 1h BS ≥ 180,2hBS ≥ 155, 3hBS ≥ 140 mg/ dl).

In the present study individuals with normal levels of T4 and T3 and TSH <0.3mlU / L had been considered as sub clinical hyperthyroidism and individuals with normal T4 and T3 and TSH> 4mlU / L as sub clinical hypothyroidism. High T4 and TSH <0.3 as hyperthyroidism and T4 <4.8 and TSH>4 as hypothyroidism.

Questionnaire included type of diabetes (GDM or pre-gestational), thyroid disease history, history of drug consumption for thyroid dysfunction, gestational age at diagnosis was completed for each patient. The data obtained in this study were analyzed by statistical software SPSS15.

**RESULTS**

This study was performed on 61 diabetic pregnant patients. Among them 22 patients (36%) had GDM and 39 (64%) had pre-gestational diabetes (20% type 1 and 80% type 2 diabetes). Control group were 35 non-diabetic pregnant women. Diabetic patients were aged 19 to 47 years. The overall mean age was 30±6.5 years in all diabetic patients and 28.9 ± 5.33 years in GDM and 30.6±7.10 years in pre-gestational diabetes. Mean age of control group was 27.7±4.25.

Among 22 patients with GDM, 21 patients (95.5%) had normal thyroid function and one patient (4.5%) had subclinical hypothyroidism. Among 39 patients with pre-gestational diabetes, 29 cases (74.4%) had normal thyroid function and 10 cases (25.6%) had thyroid dysfunction. In control group among 35 patients, three patients (8.6%) had thyroid dysfunction.

Overall Subclinical hypothyroidism was the more prevalent thyroid dysfunction in the three groups. Thyroid dysfunction was significantly higher in pre-gestational than GDM group (P = 0.037). Thyroid dysfunction in GDM and pre-gestational group did not have significant difference with control group (p =0.99, 0.054 respectively). Previous history of thyroid disease were found in 16 cases (16.3%) and all of them were in pre-gestational group.

| Throid function Groups | *No. of Normal Thyroid function (%) | No. of Hypothyroid (%) | No. of Subclinical Hypothyroid (%) | No. of hyperthyroid (%) | No. of Subclinical hyperthyroid (%) |
|-----------------------|------------------------------------|------------------------|-----------------------------------|------------------------|-----------------------------------|
| GDM                   | 21(95.5%)                          | 0(0%)                  | 1(4.5%)                           | 0(0%)                  | 0(0%)                             |
| Pre-gestational DM    | 29(74.4%)                          | 1(2.6%)                | 4(10.3%)                          | 1(2.6%)                | 4(10.3%)                          |
| Control group         | 32(91.4%)                          | 1(2.86%)               | 1(2.86%)                          | 1(2.86%)               | 0(0%)                             |

* No = number
Types of thyroid dysfunction in diabetic patients and control groups are shown in Table-I. High titer of TPO Ab was detected in 27% of the GDM group, 36% of pre-gestational DM and 23% of control group. There was no significant differences in Anti TPO positive titer between three groups (p=0.188).

DISCUSSION

About 10-15% of pregnant women have thyroid dysfunction during the first half of pregnancy. Patterns of ontogeny of fetal cerebral cortex deiodinases and thyroid hormone receptors that begin by 7-8 weeks gestation, can be an evidence that thyroid hormone is important in fetal neurodevelopment. Thyroid dysfunction specially mild or subclinical hypothyroidism is associated with impaired neurodevelopment.

Thyroid dysfunction in GDM patients had no significant difference with control group. In Luisa Ruas et al study the prevalence of thyroid dysfunction in GDM was 5.1% that is comparable with our study. In the present study, positive TPO Ab was seen in 27% of women with GDM and in 36% of pregnant women with pre-gestational diabetes and 23% of control group and there was no statistically significant difference between them.

A study in normal pregnant women in Iran reported thyroid dysfunction prevalence as 2.6% that is similar to our study. Agarwal et al study reported that thyroid dysfunction rate is similar in GDM and non-diabetic pregnant women, but Velkoska Nakova et al reported higher prevalence of hypothyroxinemia in GDM than non-diabetic controls.

In Gllas PR and Lois Jovanic P studies thyroid dysfunction in pregnant women with type 1 diabetes was 40% and 40.9% respectively; that is higher than our study. The cause of this difference may be because most of our patients had type 2 diabetes (80%) rather than type 1 diabetes (20%), whereas in Gllas PR and Lois Jovanic P study all patients had type 1 diabetes and thyroid dysfunction is higher in this group. In another study in non-pregnant diabetic women in Iran the prevalence of thyroid dysfunction was 40% in type 1 and about 20% in type 2 DM.

Gonzalez et al. also showed that 26% of pregnant women with type 1 diabetes and 4% of healthy pregnant women had thyroid dysfunction which is comparable with our study. However, Di Gilio AR and colleagues study showed no significant difference between TSH, FT4, FT3 levels in diabetic and healthy pregnant women. In this study sample size was 15 women with type 1 diabetes and 13 healthy persons, which was small and may affect the results. Gllas PR also showed the same frequency of clinical hypothyroidism as our study.

Antithyroid antibodies can cross the placenta and therefore they can influence fetal brain and neurodevelopment. Some studies showed that even without the overt thyroid dysfunction, autoimmune thyroid disease increases abortion rates up to 3 to 5 times.

In the present study, positive TPO Ab was seen in 27% of women with GDM and in 36% of pregnant women with pre-gestational diabetes and 23% of control group and there was no statistically significant difference between them.

Ortega-Gonzalez et al studied 50 healthy pregnant women, 50 GDM women and 50 pregnant women with type 2 diabetes TPO Ab> 251U/ml (strongly positive) was found in 10% of healthy women, 10% of pregnant women with type 2 diabetes and 6% in women with GDM without statistically significant difference. Luisa R et al study evaluated Tg Ab and Anti TPO Ab in 408 GDM women and reported high titer of antibodies in 5% of study population. The difference between mentioned studies and our study could be due to regional differences, race and iodine consumption. Because of consumption of iodine salt for correction of iodine deficiency in our country, it can increase thyroid auto-immunity and rise in thyroid auto antibodies titer. In Ortega study just TPO Ab > 251 U / ml (strongly positive) was considered, whereas in our study all patients with positive TPO Ab, have been considered. Bech et al also reported 17.85% positive titer of anti-microsomal antibody in a group of type 1 diabetes pregnant women.

Positive titer of auto antibody in pregnancy may be predictive of higher prevalence of post-partum thyroiditis in our population. Therefore for long term prospective studies to follow up of patients with positive antibodies and subclinical Thyroid dysfunction after delivery is recommended.

CONCLUSION

This study showed that thyroid dysfunction has a high prevalence in women with pre-gestational DM
and therefore thyroid function should be evaluated in these patients during pregnancy. Thyroid dysfunction was equally prevalent in women with GDM and normal pregnant women but 27% of them had positive titer of TPO Ab that warrants follow up for post-partum thyroiditis, dysfunction.

ACKNOWLEDGMENT
This paper is based on the thesis of Dr. Mahnaz Rahimi Baniani and financial support was provided by Diabetes Research Center, Ahvaz Jundishapur University of Medical Science (Reg.No. p/a/252).

REFERENCES
1. Metzger BE, Purdy LP, Phelps RL. Diabetes mellitus and pregnancy, ‘Endocrinology’ (third edition), Besser M, Burger H G, Loriaux L, Marshall J C, Degroot L J (Eds), WB Saunders Company, London, UK.1995:1464-1482.
2. Getahun D, Nath C, Ananth CV, Chavez MR, Smulian JC. Gestational diabetes in the United States: temporal trends 1989 through 2004. Am J Obstet Gynecol. 2008;198(5):525, e1-5.
3. Shahbazian HB, Shahbazian N, Yarahmadi M, Saiedi S. Prevalence of gestational diabetes mellitus in pregnant women referring to gynecology and obstetrics clinics. Jundishapur J Med Sci. 2012; 11(2):113-121.
4. Larjani B, Hossein-Nezhad A, Rizvi SWH, Munir S, Vassigh A. Cost analysis of different screening strategies for gestational diabetes mellitus. Endocrine Practice J. 2003;9(6):504-509.
5. Hadaegh F, Kheyrandish M, Rahimi SH, Towhid M. Prevalence of gestational diabetes in pregnant women of Bandar Abbas. Iranian Journal of Endocrinology and Metabolism. 2004; 6(3SN 23):0-0.
6. Bloomgarden ZT. Abnormal thyroid function during pregnancy.2003.Available from http://www.medscape.com/viewarticle/458428.
7. Gallas PR, Stolk RP, Bakker K, Endert E , Wiersing WM. Thyroid dysfunction during pregnancy and in the first postpartum year in women with diabetes mellitus type 1. Eur J Endocrinol. 2002;147(4):443-451.
8. Jovanovic L. Diabetes mellitus and pregnancy, ‘Principle and practice of endocrinology and metabolism’ (third edition),McAllister L, Snyder A, McLaughlin MA & Garza S(Eds), Lippincott Williams & Wilkins, Philadelphia, USA. 2001:1451-1458.
9. Agarwal MM, Dhatt GS, Punnoose J, Bishawi B, Zayed R. Thyroid function abnormalities and antithyroid antibody prevalence in pregnant women at high risk for gestational diabetes mellitus. Gynecol Endocrinol. 2006; 22(5):261-266.
10. Nakova VV, Krstevska B, Dimitrovski CH, Simeonova S, Hadzi-Lega M, Serafimoski V et al. Prevalence of thyroid dysfunction and autoimmunity in pregnant women with gestational diabetes and diabetes type 1. Prilozi. 2010;31(2):51-59.
11. Soler NG, Nicholson H. Diabetes and thyroid disease during pregnancy. Obstet Gynecol. 1997; 54(3):318-321.
12. Wilker RE, Fleischman AR, Saenger P, Pan C, Surks MI. Thyroid hormone levels in diabetic mothers and their neonates. Am J Perinatol. 1984; 1(3):259-262.
13. Cleary-Goldman J, Malone FD, Lambert-Messerlian G, Sullivan L, Canick J, Porter TF et al. Maternal thyroid hypofunction and pregnancy outcome. Obstet Gynecol. 2008; 112(1):85-92.
14. Gliner D. Thyroid function during pregnancy, ‘The thyroid’ Braverman LE, Utiger RD. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2004:1086-1100.
15. LaFranchi SH, Haddow JE, Hollowell JG. Is thyroid inadequacy during gestation a risk factor for adverse pregnancy and developmental outcomes? Thyroid. 2005;15(1):60-71.
16. Vaidya B, Anthony S, Bilous M, Shiel B, Drury J, Hutchinson S, et al. Detection of thyroid dysfunction in early pregnancy: Universal screening or targeted high-risk case finding? J Clin E Endocrinol Metab.2007; 92:203-217.
17. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child N Engl J Med. 1999;341(8):549-555.
18. El Baba KA, Azar ST. Thyroid dysfunction in pregnancy. Int J Gen Med.2012; 227-230.
19. Ruas L, Paiva S, Compos M, Elvira M, Cravo LA. Prevalence of thyroid antibodies in gestational diabetes mellitus. Bioscientifica [serial on line]. 2007; 14:338. Available from: http://www.endocrin-abstract.org/ea/0014n338.htm. Accesses May 02, 2007.
20. Mellati AO, Amir-Moghaddamy HR. Evaluation of thyroid function in pregnant women referred to clinics in Zanjan through measurement of TSH, FT4 serum. Medical Science Health Services Journal of Zanjan. 1997; 20(5):11-17.
21. Shahbazian HB, Behbahani AM. Assessment of thyroid dysfunction and thyroid auto-antibodies in type 1 diabetes. Jundishapur Journal of Medical Science. 2012; 11(1):69-76.
22. Shahbazian HB, Behbahani AM, Mohtasham AZ. Prevalence of thyroid dysfunction and thyroid antibodies in type 2 diabetic patients. Pak J Med Sci. 2011; 27(5):1169-1172.
23. Gonzalez-Jimenez F, Fernandez-Soto ML, Lobon-Hernandez JA, Lopez-Medina JA, Navarrete L, Escobar-Jimenez F, et al. Autoimmune thyroid disease and insulin-dependent diabetes mellitus during pregnancy and post-partum. Ann Ist Super Sanita. 1997; 33(3):437-439.
24. Di Gilio AR, Greco P, Vimercati A, Capursi T, Ciampolillo A, Triggiani V, et al. Incidence of thyroid diseases in pregnant women with type 1 diabetes mellitus. Acta Biomed Ateneo Parmense. 2000; 71(1):387-391.
25. Ortega-Gonzalez C, Liao-Lo A, Ramirez-Peredo J, Carino N, Lira J, Parra A. Thyroid peroxidase antibodies in Mexican-born healthy pregnant women, in women with type 2 or gestational diabetes mellitus and their offspring. Endocr Pract. 2000; 6(3):244-248.
26. Bech K, Hoier-Madsen M, Feldt-Rasmussen U, Jensen BM, Molsted-Pedersen L, Kuhl C. Thyroid function and autoimmunne manifestations in insulin-dependent diabetes mellitus during and after pregnancy. Acta Endocrinol. 1991; 124:534-539.